Ocumension Therapeutics (1477.HK) HKSE

10.45

-0.05(-0.48%)

Updated at September 08 04:08PM

Currency In HKD

Ocumension Therapeutics

Address

No. 1858 Yinzhongnan Road

Suzhou,

China

Phone

N/A

Sector

Healthcare

Industry

Biotechnology

Employees

489

First IPO Date

July 10, 2020

Key Executives

NameTitlePayYear Born
Mr. Ye LiuChief Executive Officer & Executive Director6.83M1972
Dr. Zhaopeng HuChief Development Officer & Executive Director3.61M1974
Ms. Hongying LiuChief Internal Audit Officer01978
Dr. Yang ShenChief Medical Officer01983
Mr. Qinglei ZuoChief Commercial Officer01984
Mr. Tim RuanChief Financial Officer & Joint Company Secretary01986
Ms. Tingchan ChenJoint Company Secretary01995

Description

Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. The company discovers, develops, and commercializes therapies for ophthalmic patients. It offers drugs for the treatment of blepharitis, infective and allergic conjunctivitis, dry eye, cataract, glaucoma and ocular hypertension, postoperative inflammation, uveitis, retinitis pigmentosa, age-related macular degeneration, cornea graft rejection, myopia, and optic neuritis. As of December 31, 2021, the company had 20 drug assets in its portfolio. Ocumension Therapeutics was founded in 2017 and is headquartered in Suzhou, the People's Republic of China.